Currently out of the existing stock ratings of Rachel Vatnsdal, 8 are a SELL (9.09%), 38 are a HOLD (43.18%), 42 are a BUY (47.73%).

Rachel Vatnsdal

Work Performance Price Targets & Ratings Chart

Analyst Rachel Vatnsdal, carries an average stock price target met ratio of 85% that have a potential upside of 20.43% achieved within 200 days. Previously, Rachel Vatnsdal worked at JPMORGAN.

Rachel Vatnsdal’s has documented 175 price targets and ratings displayed on 21 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on RVTY, Revvity at 03-Feb-2026.

Wall Street Analyst Rachel Vatnsdal

Analyst best performing recommendations are on TEM (TEMPUS AI).
The best stock recommendation documented was for TEM (TEMPUS AI) at 8/7/2024. The price target of $47 was fulfilled within 8 days with a profit of $8.18 (21.07%) receiving and performance score of 26.34.

Average potential price target upside

AMRS Amyris QDEL Quidel MTD Mettler-Toledo International HSIC Henry Schein DHR Danaher MYGN Myriad Genetics PACB Pacific Biosciences of California PDCO Patterson Companies RGEN Repligen A Agilent Technologies ADPT Adaptive Biotechnologies Corp AKYA Akoya Biosciences ILMN Illumina NVST Envista Holdings Corp TWST Twist Bioscience Corp TXG 10X Genomics RVTY Revvity TEM Tempus AI WAT Waters TMO Thermo Fisher Scientific NTRA Natera

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold

$0.65

$0.51 (364.29%)

$3.35

3 years 5 months 14 days ago
(18-May-2023)

2/2 (100%)

$0.06 (10.17%)

10

Buy

$1.25

$1.2 (2400.00%)

$19

3 years 5 months 22 days ago
(10-May-2023)

3/4 (75%)

$2.13 (47.39%)

21

Buy

$5

$4.86 (3471.43%)

$30

3 years 7 months 16 days ago
(16-Mar-2023)

7/10 (70%)

$3.68 (278.79%)

819

Hold

$2

$1.86 (1328.57%)

$2.5

3 years 9 months 29 days ago
(03-Jan-2023)

1/2 (50%)

$0.55 (37.93%)

2

Hold

3 years 11 months 23 days ago
(09-Nov-2022)

1/2 (50%)

$7.57 (43.43%)

391

Show more analysts

Please expand the browser size to see the chart

✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?